 |
2 Products |  |
0 Diseases | | 2 Products |
|
7 Trials |  |
90 News |  |
- || HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
Clinical, P1 data, Clinical Trial,Phase I, Journal: Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial. (Pubmed Central) - Aug 4, 2020
P1
Further investigation may be warranted into the value of EP to improve immunization outcomes. ClinicalTrials.gov NCT01496989.
- | HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
Trial completion: Therapeutic Vaccine for HIV (clinicaltrials.gov) - Mar 3, 2020
P1, N=33, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov NCT01496989. Active, not recruiting --> Completed
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
Trial primary completion date: Therapeutic Vaccine for HIV (clinicaltrials.gov) - Mar 8, 2017
P1, N=33, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Aug 2019
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
Trial completion: Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Dec 13, 2016
P1, N=100, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Feb 2017 --> Aug 2019 Active, not recruiting --> Completed
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
Enrollment closed, Enrollment change, Trial primary completion date: Therapeutic Vaccine for HIV (clinicaltrials.gov) - Feb 26, 2016
P1, N=33, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=50 --> 33 | Trial primary completion date: Jan 2030 --> Mar 2017
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
Trial primary completion date: Therapeutic Vaccine for HIV (clinicaltrials.gov) - Apr 14, 2015
P1, N=50, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | N=50 --> 33 | Trial primary completion date: Jan 2030 --> Mar 2017 Trial primary completion date: Nov 2016 --> Jan 2030
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
Enrollment closed: Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Sep 29, 2013
P1, N=100, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Nov 2016 --> Jan 2030 Recruiting --> Active, not recruiting
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
Trial completion: Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults (clinicaltrials.gov) - Jun 27, 2013
P1, N=62, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
Trial completion: Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers (clinicaltrials.gov) - Jun 11, 2013
P1, N=75, Completed, Sponsor: International AIDS Vaccine Initiative
Active, not recruiting --> Completed Active, not recruiting --> Completed
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
New P1 trial: Therapeutic Vaccine for HIV (clinicaltrials.gov) - May 19, 2013
P1, N=50, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults (clinicaltrials.gov) - Apr 15, 2012
P1, N=100, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
New P1 trial: Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers (clinicaltrials.gov) - Dec 20, 2011
P1, N=75, Completed, Sponsor: International AIDS Vaccine Initiative